Indacaterol/mometasone

Indacaterol/mometasone
Combination of
Indacaterol	Beta-2 adrenergic receptor agonist
Mometasone	Corticosteroid
Clinical data
Trade names	Atectura Breezhaler, Bemrist Breezhaler
Other names	QMF149, IND/MF
License data	EU EMA: by INN;
Routes of; administration	Inhalation
ATC code	R03AK14 (WHO) ;
Legal status
Legal status	EU: Rx-only ; In general: ℞ (Prescription only);
Identifiers
CAS Number	2447636-39-5;

Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta₂ agonists.^[1]

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).^[1] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.^[1] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,^[1] and in Japan in June 2020.^[2]

References[]

^ ^a ^b ^c ^d "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Retrieved 25 July 2020.

External links[]

"Indacaterol mixture with mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by .

[Atectura_Breezhaler_EPAR-1] "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[2] "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Retrieved 25 July 2020.

[1]

[2]